Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

NCT04416568 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Malignant Rhabdoid Tumor
Rhabdoid Tumor of the Kidney
Epithelioid Sarcoma
Chordoma (Poorly Differentiated or De-differentiated)
Atypical Teratoid/Rhabdoid Tumor
Other INI1 Negative Tumors (With PI Approval)
Other SMARCA4-deficient Malignant Tumors (With PI Approval)

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]